
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CAN-3110,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Candel Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Batavia and Candel Partner to Accelerate Development of CAN-3110
Details : The partnership aims to accelerate the development and production of CAN-3110, an oncolytic viral immunotherapy for glioma brain tumors, based on a replication attenuated Herpes Simplex Virus (HSV).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 21, 2024
Lead Product(s) : CAN-3110,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Candel Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Valneva
Deal Size : Undisclosed
Deal Type : Collaboration
Batavia Biosciences to Partner with Valneva Sweden AB for Polio Vaccine Development
Details : Under the terms of the agreement, Valneva will manufacture the sIPV vaccine for clinical trial purposes in its state-of-the-art GMP polio manufacturing facility operated under GAPIII[2] polio containment in Solna, Sweden, using Batavia’s process.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Valneva
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VSV∆G-SARS-CoV-2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : IAVI
Deal Size : Undisclosed
Deal Type : Collaboration
Details : By working with Batavia Biosciences, IAVI intends to develop an end-to-end platform for flexible, low-cost production of epidemic preparedness vaccines, including vaccines against a group of viruses that cause hemorrhagic fevers and other emerging viral...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 05, 2020
Lead Product(s) : VSV∆G-SARS-CoV-2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : IAVI
Deal Size : Undisclosed
Deal Type : Collaboration
